1. Home
  2. CSBR vs INKT Comparison

CSBR vs INKT Comparison

Compare CSBR & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Champions Oncology Inc.

CSBR

Champions Oncology Inc.

N/A

Current Price

$4.98

Market Cap

68.8M

Sector

Health Care

ML Signal

N/A

Logo MiNK Therapeutics Inc.

INKT

MiNK Therapeutics Inc.

N/A

Current Price

$12.70

Market Cap

59.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CSBR
INKT
Founded
1985
2017
Country
United States
United States
Employees
214
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.8M
59.4M
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
CSBR
INKT
Price
$4.98
$12.70
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $39.00
AVG Volume (30 Days)
★ 12.5K
12.4K
Earning Date
09-10-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $2,900,000.00
N/A
Revenue This Year
$9.83
N/A
Revenue Next Year
$8.50
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.59
$8.48
52 Week High
$8.31
$16.00

Technical Indicators

Market Signals
Indicator
CSBR
INKT
Relative Strength Index (RSI) 46.98 63.29
Support Level $4.71 $10.84
Resistance Level $6.31 $13.40
Average True Range (ATR) 0.26 0.61
MACD -0.00 0.05
Stochastic Oscillator 36.19 83.87

Price Performance

Historical Comparison
CSBR
INKT

About CSBR Champions Oncology Inc.

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment which is oncology services. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The company's pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. Its revenue is majorly derived from research services.

About INKT MiNK Therapeutics Inc.

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.

Share on Social Networks: